Day: November 28, 2025

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI®” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The application is based on data from multiple subcutaneous (SC) administration sub-studies of lecanemab conducted...

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT) (“Optiva“) is pleased to announce that the shareholders of Optiva (the “Shareholders“) and the holders (the “Noteholders“) of principal amount of 9.75% senior secured payment-in-kind toggle notes (“PIK Notes“) have approved the proposed plan of arrangement (the “Arrangement“) involving Qvantel Oy (the “Purchaser“) at the special meeting of Shareholders (the “Shareholder Meeting“) and special meeting of Noteholders (the “Noteholder Meeting” and collectively with the Shareholder Meeting, the “Meetings“) held earlier today. Pursuant to the Arrangement, (i) the Purchaser will acquire all of the issued and outstanding common shares of Optiva (the “Shares“)...